Abbott Nutritionals Rise In Stature With Departure Of Branded Rx
This article was originally published in The Tan Sheet
Abbott Laboratories’ nutrition business – one of four divisions in the remaining diversified medical products firm – gains importance with the firm’s plan to spin off its research-based branded pharmaceuticals business.
You may also be interested in...
Germany’s Merck KGaA could join the ranks of firms like Pfizer potentially looking to leave the consumer health care product business, market analysts argue.
Consumer response to Abbott Laboratories' recall of powder Similac and other infant formula products initially exceeded the firm's capabilities to handle telephone calls and support online traffic to its websites
CDRH Director Jeffrey Shuren discussed the device center’s two-year strategic priorities with “The Gray Sheet.” The center plans to rebalance pre-market and post-market data collection, when appropriate, and improve the processes for starting up clinical trials in the U.S.